Observational, Retrospective Study to Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Apr 2018
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms REALE
- Sponsors Bayer
- 04 Apr 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 28 Feb 2018 Planned initiation date changed from 31 Jan 2018 to 6 Mar 2018.
- 29 Jan 2018 New trial record